Using celecoxib for the suppression of preterm labor instead of magnesium sulfate.
We aimed to use celecoxib to suppress preterm labor instead magnesium sulfate (MgSO4) to prevent preterm labor.


METHODS
It was a randomized clinical trial study, which was done on 600 pregnant women. All subjects were divided into two groups by simple random sampling. One group was given 4 grams of MgSO4 intravenously and second group was given 100 mg of celecoxib orally every 12 hours for at least 2 days. The data were entered and analyzed using SPSS 11 and performed using t-test and chi-square test.


RESULTS
The finding of this study has shown that preterm labor may be prevented in 75.7% of subjects who had received celecoxib and there were no significant difference between two groups in frequency of history of preterm labor (P = 1), frequencies of nulliparity (P = 0.99), duration of drug use and arrest contraction (P = 0.29), delivery before 48 hours (P = 0.20), and mean gestational age in lack of response to treatment (P = 0.24).


CONCLUSIONS
Result has shown that celecoxib was similar to MgSO4 as a medication to prevent preterm labor; it was recommended to be prescribe to prevent preterm labor, because it was cheaper than magnesium sulfate.
Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Najmieh
N
Saadati
Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Farideh
F
Moramezi
Social Determinant of Health Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Maria
M
Cheraghi
Fertility, Infertility and Perinatology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Laila
L
Sokhray
D000328:Adult; D000068579:Celecoxib; D005260:Female; D005865:Gestational Age; D006801:Humans; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D007752:Obstetric Labor, Premature / Q000188:drug therapy*; D010298:Parity; D011247:Pregnancy; D011720:Pyrazoles / Q000627:therapeutic use*; D016037:Single-Blind Method; D013449:Sulfonamides / Q000627:therapeutic use*; D015149:Tocolytic Agents / Q000627:therapeutic use*; D016896:Treatment Outcome; D014590:Uterine Contraction / Q000187:drug effects
D011720:Pyrazoles; D013449:Sulfonamides; D015149:Tocolytic Agents; D008278:Magnesium Sulfate; D000068579:Celecoxib